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Abstract
Background: Neuroblastoma is a neural crest-derived tumor and is the most common cancer in children less than
1 year of age. We hypothesized that aberrations in genes that control the cell cyclecouldplayan important role in the
pathogenesis of neuroblastoma nd could provide a tractable therapeutic target.
Methods: In this study, we screened 131 genes involved in cell cycle regulation at different levels by analyzing the
effect of siRNA-mediated gene silencing on the proliferation ofneuroblastomacells.
Results: Marked reductions in neuroblastoma cellular proliferation were recorded after knockdown ofCCNDI or
P/./C/. Wenextshowedthatpharmacologicalinhibitionofcyclin D1 dependent kinases 4/6 (CDK4/6) with PD 0332991
(palbociclib) reduced the growth of neuroblastoma cell lines, induced G1 cell cycle arrest, and inhibited the cyclin
01-Rbpathway.
Conclusion: Selective inhibition ofCDK4/6 using palbociclib may provide a newtherapeuticoption fortreating
neuroblastoma.
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Background
Neuroblastoma is a solid childhood tumor that arises
from the sympathoadrenal lineage of the neural crest
during development [l]. It represents the most common
cancer in children younger than l year [2] and is a heter-
ogeneous disease that may either have a very good prog-
nosis (e.g., stage 4S neuroblastoma) or a dismal outlook
(e.g" AfYCW-amplLfied neuroblastoma) [ ]. Neural crest-
derived maügnancies uch as neuroblastoma re believed
to have defects in the regulatory circuits that are essen-
tial for embryonic development and regulation of cellular
difFerentiation, in particular at the Gl-S transition [l, 3].
The involvement ofcell cycle regulators uch as PLK1 [4],
TRIM16 [5], WEE1 [6], CD^-4/6 [7], and CCND1 [8] in
various aspects of neuroblastoma pathogenesis suggests
that deregulation of the normal cell cycle could be an
ünportant factor in drivmg neuroblastoma tumorigenesis
and opens the possibility that more oncogenic ell cycle
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regulators could be identified by screening a large set of
cell cycle regulators.
In this study, we used an siRNA library targeting 131
cell cycle regulators that belong to different gene fami-
lies involved in cell cycle regulation. The siRNA übrary
was used to assess the effect of knockdown of cell cycle
regulators on the proliferation of neuroblastoma cells.
This approach is expected to result in the identification
of genes that are required for proliferation or survival of
neuroblastoma cells, and therefore may serve as new ther-
apeutic targets. Our screen showed that several cell cycle
regulators are critical for neuroblastoma cellular prolif-
eration. The strongest reductions in cellular proliferation
were observed after knockdown of CCND1 or PLK1. To
translate these findings into a pharmacologicaüy useful
approach, we explored the potential therapeuüc utility of
palbociclib, a small-molecule inhibitor of cyclin Dl asso-
ciated kinases, mainly CDK4 and CDK6. We showed that
palbociclib, which is widely used in cünical trials, inhib-
its the growth of neuroblastoma cells in vitro. Moreover,
ceU cycle analysis demonstrated that palbocicüb induces
cell cycle arrest exclusively in Gl. In addition, we showed
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that inhibiting CDK4/6 by palbociclib suppresses the cyc-
lm Dl-pRb pathway by inhibiting the phosphorylation of
Rb and the expression of E2F target genes. Our data sug-
gest that the CDK4/CDK6 inhibitor palbocicUb may offer
therapeuüc benefit for the treatment ofneuroblastoma.
Results
Screening of neuroblastoma cellular proliferation using an
siRNA library of 131 cell cycle regulators
We used an siRNA library to target 131 cell cycle regula-
tors in two neuroblastoma cell lines (NGP and IMR-32)
followed by moiütoring of neuroblastoma cell growth in
real time. The siRNA library included siRNAs that tar-
get genes which belang to several gene famiües involved
in cell cycle regulation at different levels, such as cyclin
dependent kinases (CDKs), members of the retinoblas-
toma protein family, DNA replication factors like the cell
division cycle proteins (CDCs), members of the CIP/KIP
family, and the INK4 family of cell cycle inhibitors. Our
results showed that several genes of these families are
required for the growth of both NGP and IMR-32 cells.
In particular, silencing of CCND1 and PLK1 showed the
most pronounced effects in reducing neuroblastoma cel-
lular proliferation (Fig. l; Additional file l: Table Si).
Knockdown ofCCNDI m neuroblastoma cell lines
CCND1 and PLK1 were the primary hits of oor siRNA
übrary screen. As inhibition ofPLKl using small molecule
compounds has already been extensively studied in neu-
roblastoma [4, 9], we decided to select CCND1 for further
experiments. We first measured the mRNA expression
levels of CCND1 m a panel of 31 neuroblastoma cell lines
(Additional file l: Figure SI) and evaluated the effects of
CCND1 knockdown on the proliferation of eight neuro-
blastoma cell Unes in real time using the xCELLigence sys-
tem, The cell lines had various levels of CCND1 expression
and were either MYCN amplified or MYCN nonamplified
and either mutant or wild-type for TPS3 (Additional file l:
Table S2). Our results showed that knockdown of CCND1
induces a reduction in cellular proliferation in the major-
ity of the neuroblastoma cell lines in comparison to the
scrambled siRNA negative control (Fig. 2). The real-tüne
data is shown in Additional file l: Figure S2.
Targeting the cyclin D1-CDK4/CDK6 complex
with patbociclib
Targeting cyclin Dl with smaU molecule compounds is
currently not possible. However, an alternative approach
to inhibit its activity is by inhibiting the associated
kinases, CDK4 and CDK6. Indeed, a small molecule
compound known as PD 0332991 or palbociclib has been
reported to be a potent and highly selective inhibitor of
CDK4 and CDK6 [10]. We treated neuroblastoma cells
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Fig. 1 siRNA library screening ofcell cycle regulators. NGP cells (a)
and IMR-32 cells (b) weretransfected with the siRNA library induding
negativo controls (scrambled siRNA) and their growth was assessed
using the xCELLigence system.The data shown in the graphs
represent he cellular proliferation measurements recorded at 48 h
post transfection. The data are depicted as Z score values (Additional
file 1:Table S1), which represent he number of standard deviations
from the average for every measurement. Positive Z score values
indicate an increase in cell growth, whereas negative values represent
a decrease in cell growth.
with this compound and evaluated the effect on cellular
proliferation using xCELLigence. Our results showed
that palbocidib inhibits the growth ofIMR-32, SH-SY5Y,
and NGP cells in a time- and dose-dependent manner. In
contrast, other neuroblastoma cell lines such as SK-N-SH
and CLB-GA were relatively resistant o the treatment.
Other cell lines such as SH-EP responded at relatively
high concentraüons (Fig. 3). IC50 values are shown in
Table l and the real-time data is shown in Additional
file l: Figure 53. The effect of palbociclib on the prolif-
eration of neuroblastoma cells is very similar to the effect
induced by the knockdown of CCND1, which suggests
that both treatments induce their effects by targeting the
same pathway.
Palbociclib induces G1 arrest in neuroblastoma cells
We evaluated the effect of palbociclib on the progression
of the cell cycle in the neuroblastoma cell lines. The cells
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Fig. 2 Assessment ofcellular proliferation after knockdown ofCCNDï. The cellular proliferation was measured in real time using the xCELLigence
system. The data shown represents the percentage of cellularproliferationafter 72 hofknockdownofCCWDï.A/CscrambledsiRNAnegativecontrol.
Errorbars represent he standard deviation (n = 2).
were exposed to vehicle control (O ytM) or l [iM of pal-
bociclib for 24 h. Cell cycle analysis howed that palbo-
ciclib induces an increase in the percentage of cells in G l
and a decrease in the other phases of the cell cycle in the
neuroblastoma cell lines (Fig. 4). This induction of a Gl
ceU cycle arrest is consistent with what is expected after
selective inhibiüon ofCDK4 and CDK6 [10].
Palbociclib inhibits Rb phosphorylation and the Rb/E2F
pathway in neuroblastoma cells
The cyclin D1-CDK4/6 complex specifically phos-
phorylates Rb at Ser780 [11]. Reduction in Rb
phosphorylation at Ser780 is indicative of CDK4 and
CDK6 inhibition. Upon treatment of neuroblastoma
cells with 0, 250, 500, or 1,000 nM of palbocidib, we
evaluated the degree of Rb phosphorylation by West-
ern blot analysis. Treatment with palbociclib inhibited
the phosphorylation of Rb in a dose-dependent man-
ner only in the cells that showed a decrease in cellu-
lar proliferation after palbociclib treatment (Fig. 5a).
Phosphorylation of Rb by the cyclin D1-CDK4/6 com-
plex releases E2F from the inhibitory grip of Rb [12].
Therefore, hypophosphorylation of Rb due to inhibi-
tion of CDK4/6 should lead to the inhibition of E2F
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: Fig. 4 Cellcydeanalysisaftertreatmentwithpalbodclib. DNAhistograms generated byflowcytometryforneuroblastoma cell lines treated with
palbocidibfor24h.TheDNAhistogramsshowthedistributionofcellpopulationsineach phase of the cellcyde. The percentages of cells are
shown to the right of each histogram.
required for the proliferaüon or survival of neuroblas-
toma cells and that might serve as new therapeutic tar-
gets. The gene famüies included cyclin dependent kinases
(CDKs), members of the retinoblastoma protein family,
DNA replication factors such as the cell division cycle
proteins (CDCs), members of the CIP/KIP family, and
the INK4 famüy of cell cycle inhibitors. Real-time moni-
toring of cell growth showed that knockdown of CCND1
and PLK1 had the strongest effects in reducing the pro-
liferation of neuroblastoma cells. PLK1 has previously
been extensively studied in neuroblastoma nd has been
shown to inhibit he transactivation activity of p53 and
to promote cell survival [4, 13, 14]. Moreover, targeting
PLK1 with small molecule compounds induced apopto-
sis and growth arrest in neuroblastoma tumor-initiating
cells [5, 9] and reduced the growth of neuroblastoma
xenografts in nude mice [4, 6]. Cyclin Dl has also been
studied to some extent in neuroblastoma nd has previ-
ously been shown to be highly expressed in a subset of
neuroblastoma cell lines and tumors due to gene ampli-
fication or GATA3 binding [7, S, 15 16]. Cyclin Dl
belongs to a group of proteins known as cyclins, which
are involved in the temporal coordination ofeach mitotic
event during the cell cycle. Cyclins exhibit a cell-cycle
dependent pattern of expression and degradation, and
they activate the CDKs. Cycün-CDK complexes phos-
phorylate target proteins uch as Rb and coordinate the
progression into the next phase of the cell cycle [8, 12].
Cyclin Dl activates CDK4 and CDK6 and this initiates
the phosphorylation of the tumor suppressor protein Rb
resulting in the activation ofE2F. The activity ofE2F leads
to the transcriptional activation of E2F-responsive genes,
such as TOP2A, CCNE2, and TK1, that are essential for
DNA synthesis and ceU cycle progression [4, 9, 10, 17].
Despite being an attracüve therapeuüc target, small mol-
ecule compounds that can directly and specifically inhibit
cyclin Dl do not exist at present. It is possible, however,
to inhibit cyclin Dl indirectly by several means. For
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Palbociclib inhibits Rb Ser780 phosphorylation a d reduces the expression of E2F target genes. Neuroblastoma cell ines were treated with
different concentrations of palbociclib for 24 h. Western blot analysis was performed using anti-Rb Ser730 to detect specific phosphorylation ofRb at
Ser780. Anti-Rb was used to detect total Rb, and anti-p actin as a loading control (a). RT-qPCR data of NGP and IMR-32 cells showing the expression
levels of E2F target genesafter 24 hof treatmentwith palbocidib. Error bars represent the standard errorofthemean(n =2) (b).
example, inhibition of CCND1 can be achieved by mTOR
inhibitors, since CCND1 mRNA translation is mTOR-
dependent [10, 18], or by inhibitors ofglycogen synthase
kinase 3 P (GSK3p), which phosphorylates cyclin Dl at
Thr-286 suggested to regulate the turnover and the intra-
cellular distribution ofcyclin Dl [10, 19]. The most effec-
tive approach to inhibit cyclin Dl activity is by inhibiting
its associated kinases CDK4 and CDK6 [11, 12]. Pan-
CDK inhibitors can inhibit CDKs but induce also con-
siderable toxicity due to ofF-target effects [12, 20]. In
contrast, early phase clinical trials have shown that spe-
cific and potent inhibition of CDK4/6 by smaü molecule
drugs, such as palbociclib [4, 21-24] and R547 [5, 25],
can result in antitumor activity with tolerable side effects.
Recently, it has been shown that inhibition of CDK4/6
by LEE011 reduces the growth of neuroblastoma tumors
with M.YCN amplification in marine xenograft models
[7]. In this study, we used palbociclib, a selecüve CDK4/6
inhibitor that has already shown promising anütumor
activity in several clinical trials in other cancer types [12].
Treatment of neuroblastoma cells in vitro with palboci-
clib resulted in variable effects; some cell lines, such as
IMR-32, SH-SY5Y, and NGP, were sensitive, whereas
other cell lines, such as SK-N-SH and CLB-GA, were
relatively resistant. It is worth mentioning that NGP cells
have CDK4 amplification. Additional studies are needed
to explain the different sensitivity to this compound.
Conclusions
We show that palbocidib induces a Gl cell cycle arrest
in neuroblastoma cells, which is in line with previ-
ous reports in other cancer types [10]. Palbociclib also
induces hypophosphorylation of Rb at Ser780, indicative
of CDK4/6 inhibition, in those neuroblastoma cell lines
that show a reduction in cellular proliferation after treat-
ment. Upon hypophosphorylation, Rb forms a complex
with E2F and we show that treatment with palbociclib
reduces the expression levels ofE2F target genes involved
m cell cycle progression, such as TOP2A, CCNE2, and
TK1. Taken together, ow results suggest hat inhibition
of CDK4/6 may provide an effective strategy to treat a
subset ofneuroblastoma tumors.
Methods
Cell lines and palbociclib treatment
Neuroblastoma cell lines were grown as monolayer
cultures at 37°C and 5% CO^ in a humid atmosphere.
The culture medium was RPMI 1640 (GIBCO, Life
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Technologies) containing 10% Fetal Calf Serum (FCS),
2 mmol/1 glutamine, and the following antibiotics: Peni-
cillin (1%), Kanamycin (1%), and Streptomycin (1%). Pal-
bociclib (Selleck Chemicals) was dissolved in DMSO and
stored as a 10 mmol/1 stock solution at -20°C. Keeping
the final concentration of DMSO constant, cells were
treated with palbociclib ranging from O to 2 |jmol/l for
the time periods indicated.
siRNA transfection
Neuroblastoma cells were seeded in RPMI 1640 (GIBCO,
Life Technologies) with 10% FCS and without antibiotics
and transfected with the siRNA library against 131 cell
cycle regulators (Dharmacon Cell Cycle ON-TARGET-
plus, Thermo Scientific) at a concentration of 100 nM
using Dharmafect 2 transfection reagent (Thermo Scien-
tific). The genes targeted by the siRNA library are listed
in Additional file l: Table S3. Transfections with siRNA
against CCND1 and scrambled negative control siRNA
were done using smart pools of siRNAs (Dharmacon,
Thermo Scientific).
Cell growth assessment
xCELLigence MP (Roche Diagnostics) was used to mon-
kor cell proliferation i  real time. Background imped-
ance was measured before seeding the cells using 40 [i\
of RPMI 1640 containing 10% FCS and always sub-
tracted as blank value. l x 104 cells in 50 \ü. of RPMI
contaüüng 10% FCS were added. Cell proliferation was
measured with a programmed signal detection every
l h and the signal was normalized to the transfection
or palbociclib treatment ime point where the cell index
at every time point was divided by the cell index at the
time of transfection. Data acquisition and analysis was
performed with the RTCA software (version 1.2, Roche
Diagnostics). IC50 values were defined as the drug con-
centration that inhibited cell proüferation by 50% at 48 h
of treatment and were calculated using GraphPad Prism
(version 6).
RNA extraction and RT-qPCR (reverse
transcription-quantitative polymerase chain reaction)
Analysis of gene expression was performed by RT-
qPCR according to MIQE guidelines [26]. RNA extrac-
tion, cDNA synthesis and RT-qPCR were performed as
described previously [27]. The primers were designed
using an in-house developed web tooi (http://www,
primerXL.org) and the sequences can be found in Addi-
tional file l: Table S4. HMBS, HPRT1, SDHA, TBP,
and YWHAZ were used for normalization. Biogazelle's
qbase + qPCR data-analysis software version 3.0 [28]
was used to quantify the relative expression of the
genes.
Western blot
Neuroblastoma cells treated with palbociclib (Selleck
Chemicals) for 24 h were harvested and washed using
ice-cold PBS, centrifuged and the supernatant discarded.
The pellet was solubilized in RIPA lysis buffer (Pierce)
contaüüng protease and phosphatase inhibitor mixture
(Roche). Cell lysates were placed on ice for 30 min and
centrifuged for 10 min at 12,000 rpm at 4°C. The pro-
tein concentration was measured using the Bio-Rad Pro-
tein Assay (Bio-Rad). Protein samples were mixed at 1:1
ratio with Laemmli denaturation buffer (Bio-Rad) and
P-mercaptoethanol (Sigma Aldrich) at a final dilution of
1/40 and boiled for 10 min at 95°C. Approximately 25 \ig
ofprotein was loaded and fractionated using a 10% SDS-
PAGE gel (Bio-Rad). The protein was transferred onto a
nitrocellulose membrane (Bio-Rad) and immunoblotted
with rabbit monodonal antibody against phospho-Rb
(Ser780) (Cell Signaling Technology), rabbit polyclonal
antibody against otal Rb (Abcam), and mouse monoclo-
nal antibody against P-actin (Sigma Aldrich) as a loading
control. Secondary antibody was anti-mouse HRP-Iinked
(Cell Signaling Technology) and anti-rabbit HRP-linked
(Cell Signaling Technology). Visualization of the proteins
was done using ChemiDoc-It Imaging System (UVP,
Sopachem).
Cell cycle analysis
Neuroblastoma cells were treated with palbociclib for
24 h, harvested, washed with PBS and resuspended in
100 ^  ofPBS. 100 \d of DNA Prep lysis buffer (Beekman
Coulter) was added to the cells and the suspension was
vortexed and incubated for 5 min. The DNA was stained
using 2 mi DNA Prep stain (Propidium iodide) and the
suspension was placed in the dark for 30 min at room
temperature. Cellular DNA content was analyzed using
the S3 cell sorter (Bio-Rad),
Additional file
Additional file 1. Real-time viability data, expression data and primers
sequences.
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